CytomX Therapeutics Reports 2023 Financial Results and : vim

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase...

Related Keywords

United States , Stephanie Ascher , Chris Ogden , Sean Mccarthy , Bristol Myers Squibb , Twitter , Amgen , Linkedin , Nasdaq , Cytomx Therapeutics Inc , Drug Administration , Quarter Business Highlights , Investigational New Drug , Bayesian Optimal Interval , Key Milestones , Annual Report , Cytomx Therapeutics , Media Contact , Ended December , Nasdaq Ctmx , Ytomx Therapeutics Inc ,